Companies › Ever Neuro Pharma
1 active drug program in 3 registered trials: 1 Phase 2, 1 Phase 4, 1 Phase 1; Neurology, Cardiovascular; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Cerebrolysin Neuroprotective peptide preparation from porcine brain | – | Phase 2 | Cadasil; Disorder of Consciousness; Bell Palsy | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05821075 | Cerebrolysin | Phase 1 | Bell Palsy | Neurology | Jan 2026 |
| NCT05755997 | Cerebrolysin | Phase 2 | Cadasil | Cardiovascular | Dec 2026 |
| NCT04427241 | Cerebrolysin | Phase 4 | Disorder of Consciousness | Neurology | Dec 2026 |
No annotated target.
–
AMO Pharma Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) Translational Sciences Edgewise Therapeutics CSPC Mingfule Pharmaceutical (Guangzhou)
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.